CorMedix Inc, Howmet Aerospace Inc Pref, Triple Flag Precious Metals Corp. Read The Tokenist (Timothy Fries)'s latest article on Investing.com ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch. The ...

These strategic moves are expected to enhance CorMedix's commercial opportunities and provide early validation for DefenCath's value proposition in preventing End-Stage Renal Disease-Catheter-Related ...

Signs and symptoms of CRBSI are nonspecific. Fever is the most common clinical sign of CRBSI and all febrile episodes in children with CVCs must be investigated for CRBSI. Particular attention ...

For all cases of CRBSI, if the CVC is no longer needed for management of the patient, it should be removed. Empiric antimicrobial therapy regimens for suspected CRBSI should be developed based on ...

Biopatch is recommended in skin sterilization protocol to reduce the incidence of CRBSI. Patients at risk of CRBSI are the ones in ICUs, those receiving chemotherapy and patients undergoing ...

reducing the risk of catheter-related bloodstream infections (CRBSI) significantly [1]. The combination’s broad-spectrum action, targeting both bacteria and fungi, makes it a promising choice.